Client Extranet
|
Site Map
|
RSS
About Us
Practices
People
Offices
News & Insights
Alumni
Careers
Blogger
Delicious
Digg
Facebook
LinkedIn
Twitter
Email
Home
»
People
»
Pamela Furman Forrest
» News & Insights
Pamela Furman Forrest (Pam)
Partner
WASHINGTON, D.C.
T: +1 202 661 7888
F: +1 202 626 3737
E-mail
CLOSE
[x]
All Offices
Abu Dhabi
Atlanta
Austin
Charlotte
Dubai
Frankfurt
Geneva
Houston
London
Moscow
New York
Paris
Riyadh
San Francisco
Silicon Valley
Singapore
Washington, D.C.
All Practices
ANDA Hatch-Waxman Litigation
Antitrust
Antitrust & IP
Antitrust Counseling
Antitrust Energy
Cartel Litigation
Civil Antitrust Litigation
EU Competition
Healthcare Antitrust
M&A / Joint Ventures
Pharma Antitrust Solutions
UK Competition and Regulatory
Appellate, Constitutional and Administrative Law
Asian Practice
Asset Management
Bankruptcy/Restructuring
Class Action
Climate Change
Commercial Disputes
Congressional Investigations
Construction and Procurement
Construction and Real Estate
Copyright
Corporate Espionage & Competitive Intelligence
Corporate Finance
Corporate Governance
Corporate Plaintiffs Litigation
Crisis Management
Congressional Investigations
Defense Industry
Energy
Financial Institutions
Food
Healthcare
Pharma/Biotech/Med Devices
Privacy & Information Security
Domestic Arbitration/ADR
E-Commerce
E-Discovery
Emerging Growth
Employee Benefits & Executive Compensation
Energy & Natural Resources
Arbitration
Construction and Procurement
Construction Dispute Resolution
Environmental Health & Safety
Environmental Litigation
Finance
Financial Restructuring
Foreign Corrupt Practices Act
Intellectual Property
LNG
Maritime
Mergers and Acquisitions
Mining and Natural Resources
Nuclear
Oil & Gas
Oil & Gas Exploration and Production
Oil & Gas Litigation
Oil & Gas Midstream and Pipelines
Oil & Gas Oil Field Services
Oil & Gas Refining
Petrochemical
Power
Power Litigation
Private Equity
Project Development
Regulatory
Renewable/Alternative Energy
Tax
Tort Litigation
Environmental Counseling
Environmental Litigation
Environmental Transactional
ERISA & Employee Benefits Litigation
FDA & Life Sciences
Financial Markets
Distressed Assets
Financial Markets Policy
Financial Services
Financial Services Litigation
First Amendment/Defamation
Franchise & Distribution
Franchise & Distribution Litigation
German Practice
Government Advocacy & Public Policy
Healthcare Industry
Academic Medical Centers
Antitrust
Children’s Health
Civil Litigation
Class Actions
Clinical Research Compliance
Environmental Health & Safety
Financial Restructuring
Government Advocacy/Public Policy
Government Investigations/FCA
Health Information Privacy & Security
Healthcare M&A
Healthcare Reform Task Force
Information Technology/EHRs
International Healthcare
Labor & Employment
Managed Care, Health Plans and Insurers
Private Equity
Provider Representation
RAC & MIC Audits and Appeals
Regulatory and Compliance
Reimbursement
Tax
Tax Exempt Bond Financings
Healthcare Litigation
Homeland Security
Infrastructure Finance
Insurance Coverage and Recovery
Intellectual Property
IP Tech Center
International
International Arbitration
International Trade/WTO
Islamic Finance
Arbitration
Asset Finance
Energy
Healthcare
Middle East & North Africa
Petrochemicals and Refining
Power and Water
Private Equity
Private Equity/Investment Funds
Project Finance
Projects and Construction
Real Estate
Saudi Arabia Practice
Joint Ventures / Strategic Alliances
Labor & Employment
Latin America Practice
Licensing
Marketing & Advertising Litigation
Mass Tort
Mergers & Acquisitions
Our Approach to Litigation
Outsourcing
Patents
Pharma/Biotech/Med Devices
Antitrust
Business Litigation
Corporate
Emerging Companies
Government Advocacy
Government Investigations
Intellectual Property
International Arbitration
Labor & Employment
Products Liability/Mass Tort
Political Law
Privacy & Information Security
Private Equity/Investment Funds
Private Finance
Product Liability Litigation
Professional Liability Litigation
Project & Equipment Finance
Public Finance
Real Estate
Russia Practice
Section 337 Investigations
Shareholder and Securities Litigation
Special Matters/Government Investigations
Sports, Media & Entertainment
Tax
Tax Litigation
Tax-Exempt
Technology Transactions
Telecommunications
Toxic Tort Litigation
Trade Secrets & Non-Compete Litigation
Trademarks/False Advertising
Advanced Search
Profile
|
Matters
|
News & Insights
NEWS
More
03 Jun 2013
RECOGNITION
Legal 500 Recognizes King & Spalding’s with 20 practice, 87 lawyer rankings in 2013 US Edition
23 Aug 2012
RECOGNITION
King & Spalding Lawyers Earn 232 Listings in 2013 Best Lawyers in America Guide
31 Aug 2011
RECOGNITION
King & Spalding Lawyers Earn 203 Listings in 2012 Best Lawyers in America Guide
30 Sep 2010
THOUGHT LEADERSHIP
King & Spalding Medical Device Summit Set for Oct. 13-14
PUBLICATIONS
More
21 May 2013
CLIENT ALERT
FDA 510(k) Rescission Authority Upheld - U.S. District Court Finds for FDA in ReGen Litigation
11 Mar 2013
CLIENT ALERT
FDA's Proposed Rule on Device Clinical Studies
07 Mar 2013
CLIENT ALERT
FDA Issues Final Guidance on Financial Disclosure by Clinical Investigators
28 Feb 2013
CLIENT ALERT
FDA Issues Draft Guidance on Medical Device Recalls
EVENTS
17 Oct 2012
CONFERENCE
West Coast Medical Device Summit
PRACTICE AREAS
FDA & Life Sciences
Healthcare Industry
MEMBERSHIPS
American Health Lawyers Association
Advisory Board of BNA’s Medical Devices Law & Industry Report
EDUCATION
J.D., Stanford University
B.A.,
summa cum laude, Phi Beta Kappa
, Yale University
ADMISSIONS
District of Columbia
New York
